Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044530856> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W3044530856 endingPage "1031" @default.
- W3044530856 startingPage "1025" @default.
- W3044530856 abstract "Introduction The globally rampant SARS CoV-2 pandemic requires novel medical strategies to control the severity of disease and death due to complications. Of the 15–20% patients that develop pulmonary symptoms, a sub-set develops an acute respiratory distress syndrome (ARDS) rapidly progressing into a critical condition. Marked elevation of cytokines/chemokines is observed with elevation of additional markers of inflammation, coagulation, and organ damage such as CRP, D-dimer, LDH, Ferritin and Troponin-I. This hyperinflammation leads to worsening of oxygen saturation due to pulmonary infiltration and exudation, organ damage, and dysfunction of coagulation pathway and may lead to multi-organ failure.Areas Covered The role of anti-inflammatory monoclonal antibodies such as Itolizumab, in cytokine storm.Expert Opinion Itolizumab, an anti-CD6 humanized IgG1 mAb, binds to domain-1 of CD-6 that is responsible for priming, activation, and differentiation of T-cells. Itolizumab significantly reduces T-cell proliferation along with substantial downregulation of the production of cytokines/chemokines. Approved for moderate to severe chronic plaque psoriasis in 2013 it is currently being studied for addressing COVID-19 related cytokine storm and its complications. This article reviews its use in COVID-19 infections; its dose, administration protocol, contra-indications, and safety in treating moderate-to-severe ARDS by preventing and treating the cytokine storm and its complications." @default.
- W3044530856 created "2020-07-29" @default.
- W3044530856 creator A5033769407 @default.
- W3044530856 creator A5041082309 @default.
- W3044530856 creator A5071740303 @default.
- W3044530856 date "2020-07-29" @default.
- W3044530856 modified "2023-10-05" @default.
- W3044530856 title "Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications" @default.
- W3044530856 cites W1480587204 @default.
- W3044530856 cites W1489752262 @default.
- W3044530856 cites W1872411639 @default.
- W3044530856 cites W2014381340 @default.
- W3044530856 cites W2731611291 @default.
- W3044530856 cites W2757349481 @default.
- W3044530856 cites W3008827533 @default.
- W3044530856 cites W3018517500 @default.
- W3044530856 cites W3021377320 @default.
- W3044530856 cites W3022155659 @default.
- W3044530856 cites W3023088605 @default.
- W3044530856 cites W3025089998 @default.
- W3044530856 cites W3026402757 @default.
- W3044530856 cites W3034129242 @default.
- W3044530856 cites W3034328821 @default.
- W3044530856 cites W3034475813 @default.
- W3044530856 cites W3036398841 @default.
- W3044530856 cites W3165656738 @default.
- W3044530856 cites W605729605 @default.
- W3044530856 doi "https://doi.org/10.1080/14712598.2020.1798399" @default.
- W3044530856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32700604" @default.
- W3044530856 hasPublicationYear "2020" @default.
- W3044530856 type Work @default.
- W3044530856 sameAs 3044530856 @default.
- W3044530856 citedByCount "28" @default.
- W3044530856 countsByYear W30445308562020 @default.
- W3044530856 countsByYear W30445308562021 @default.
- W3044530856 countsByYear W30445308562022 @default.
- W3044530856 countsByYear W30445308562023 @default.
- W3044530856 crossrefType "journal-article" @default.
- W3044530856 hasAuthorship W3044530856A5033769407 @default.
- W3044530856 hasAuthorship W3044530856A5041082309 @default.
- W3044530856 hasAuthorship W3044530856A5071740303 @default.
- W3044530856 hasBestOaLocation W30445308561 @default.
- W3044530856 hasConcept C126322002 @default.
- W3044530856 hasConcept C13373296 @default.
- W3044530856 hasConcept C203014093 @default.
- W3044530856 hasConcept C2776348555 @default.
- W3044530856 hasConcept C2776914184 @default.
- W3044530856 hasConcept C2777714996 @default.
- W3044530856 hasConcept C2778690821 @default.
- W3044530856 hasConcept C2778734968 @default.
- W3044530856 hasConcept C2779134260 @default.
- W3044530856 hasConcept C2779559532 @default.
- W3044530856 hasConcept C3008058167 @default.
- W3044530856 hasConcept C524204448 @default.
- W3044530856 hasConcept C71924100 @default.
- W3044530856 hasConceptScore W3044530856C126322002 @default.
- W3044530856 hasConceptScore W3044530856C13373296 @default.
- W3044530856 hasConceptScore W3044530856C203014093 @default.
- W3044530856 hasConceptScore W3044530856C2776348555 @default.
- W3044530856 hasConceptScore W3044530856C2776914184 @default.
- W3044530856 hasConceptScore W3044530856C2777714996 @default.
- W3044530856 hasConceptScore W3044530856C2778690821 @default.
- W3044530856 hasConceptScore W3044530856C2778734968 @default.
- W3044530856 hasConceptScore W3044530856C2779134260 @default.
- W3044530856 hasConceptScore W3044530856C2779559532 @default.
- W3044530856 hasConceptScore W3044530856C3008058167 @default.
- W3044530856 hasConceptScore W3044530856C524204448 @default.
- W3044530856 hasConceptScore W3044530856C71924100 @default.
- W3044530856 hasIssue "9" @default.
- W3044530856 hasLocation W30445308561 @default.
- W3044530856 hasOpenAccess W3044530856 @default.
- W3044530856 hasPrimaryLocation W30445308561 @default.
- W3044530856 hasRelatedWork W1994888681 @default.
- W3044530856 hasRelatedWork W2052029498 @default.
- W3044530856 hasRelatedWork W2070463916 @default.
- W3044530856 hasRelatedWork W2126005292 @default.
- W3044530856 hasRelatedWork W2146036781 @default.
- W3044530856 hasRelatedWork W3034529698 @default.
- W3044530856 hasRelatedWork W3160595368 @default.
- W3044530856 hasRelatedWork W3216059947 @default.
- W3044530856 hasRelatedWork W4205132829 @default.
- W3044530856 hasRelatedWork W4224839121 @default.
- W3044530856 hasVolume "20" @default.
- W3044530856 isParatext "false" @default.
- W3044530856 isRetracted "false" @default.
- W3044530856 magId "3044530856" @default.
- W3044530856 workType "article" @default.